New pharmacological treatments for ADHD. A case report
Downloads
Published
2018-08-15
How to Cite
Vidal Pérez, P., Vallejo Valdivieso, M., Molina Ruiz, R., Saiz Pérez, I., López Villarreal, A., & Fernández Jaén, A. (2018). New pharmacological treatments for ADHD. A case report. Revista De Psiquiatría Infanto-Juvenil, 34(3), 355–359. https://doi.org/10.31766/revpsij.v34n3a5
Issue
Section
Case reports
DOI:
https://doi.org/10.31766/revpsij.v34n3a5Keywords:
Attention Deficit Hyperactivity disorder (ADHD), Guanfacine Extended Release (GXR), Psychostimulants, Non-stimulants, Oppositional Defiant disorder (ODD)Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental disorders in childhood, which shows diagnostic persistence and morbidity into adulthood.
Psychostimulants are generally first-line pharmacotherapy for ADHD, but some patients do not achieve symptomatic remission, especially those who have Oppositional Defiant Disorder (ODD) comorbidity. In those cases, there is growing evidence that a combination of psychostimulants and nonscheduled medications to manage ADHD, may be useful.
The alpha-2 adrenergic agonist guanfacine extended release (GXR), a non-stimulant treatment, has recently been approved by the European Medicines Agency (EMA) as new therapeutic option for ADHD. In Spain it has been available from the end of January 2017.
The aim of this study is to test the efficacy and tolerability of a combined therapy of psychostimulant (lisdexamfetamine) and GXR in a patient with ADHD and ODD.
Downloads
Download data is not yet available.
References
1. Alda JA, Soutullo C, Ramos-Quiroga JA, Quintero J, Hervás A, Hernández-Otero I, et al. Expert Recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr 2014; 42 (supl 1): 1-16.
2. Escobar R, Hervás A, Soutullo C, Mardomingo MJ, Uruñuela A, 83. Gilaberte I. Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children. Actas Esp Psiquiatr 2008; 36: 285-94.
3. Faraone SV, Biederman J, Mick E. The agedependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36: 159-65.
4. Biederman J, Mick E, Faraone S V. Agedependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-8.
5. American Psychiatric Association. Disorders usually first diagnosed in infancy, childhood and adolescence. In: Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association, 2000: 85-93.
6. Steiner H, Remsing L, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 126-41.
7. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005; 57: 1215-20.
8. Alamo C, López-Muñoz F, Sánchez-García J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr 2016; 44: 107–12.
9. López-Muñoz F, Álamo C, Quintero-Gutiérrez FJ, García-García 536 P. A bibliometric study of international scientific productivity in attentiondeficit hyperactivity disorder covering the period 1980-2005. Eur Child Adolesc Psychiatr 2008; 17: 381-91.
10. McCracken JT, McGough JJ, Loo SK, Levitt J, Del’Homme M, Cowen J, Sturm A, et al. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry 2016; 55: 657–666.
11. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended- release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51: 74–85.
12. Connor DF, Findling RL, Kollins SH, Sallee F, López FA, Lyne A, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010; 24: 755–68.
13. Findling RL, McBurnett K, White C, Youcha S. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2014; 24: 245–52.
2. Escobar R, Hervás A, Soutullo C, Mardomingo MJ, Uruñuela A, 83. Gilaberte I. Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children. Actas Esp Psiquiatr 2008; 36: 285-94.
3. Faraone SV, Biederman J, Mick E. The agedependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36: 159-65.
4. Biederman J, Mick E, Faraone S V. Agedependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-8.
5. American Psychiatric Association. Disorders usually first diagnosed in infancy, childhood and adolescence. In: Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association, 2000: 85-93.
6. Steiner H, Remsing L, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 126-41.
7. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005; 57: 1215-20.
8. Alamo C, López-Muñoz F, Sánchez-García J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr 2016; 44: 107–12.
9. López-Muñoz F, Álamo C, Quintero-Gutiérrez FJ, García-García 536 P. A bibliometric study of international scientific productivity in attentiondeficit hyperactivity disorder covering the period 1980-2005. Eur Child Adolesc Psychiatr 2008; 17: 381-91.
10. McCracken JT, McGough JJ, Loo SK, Levitt J, Del’Homme M, Cowen J, Sturm A, et al. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry 2016; 55: 657–666.
11. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended- release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51: 74–85.
12. Connor DF, Findling RL, Kollins SH, Sallee F, López FA, Lyne A, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010; 24: 755–68.
13. Findling RL, McBurnett K, White C, Youcha S. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2014; 24: 245–52.
© 2021 AEPNyA Todos los derechos reservados
